August 6, 2024
The fight against online health misinformation just got a powerful new tool. In a timely three-part series titled, “A Public Health Call to Arms: The Long Road to FDA’s Misinformation Guidance,” MM+M delves into the FDA’s much-anticipated guidance on how pharmaceutical brands can address misleading health content from digital creators.
This insightful series, penned by Marc Iskowitz, features expert commentary from GCI Health’s own Global Chief Content Officer, David Chadwick. Chadwick provides crucial insights for understanding and effectively leveraging this new guidance to counter misleading social media content.
While acknowledging the limitations, Chadwick highlights the potential impact of the guidance, stating that it “… could be a difference-maker in terms of correcting the record in the interest of public health.”
This series is a must-read for anyone involved in health communications, offering valuable perspectives for navigating the complex landscape of online health information.
Dive into the article here.